Pulmonx (NASDAQ:LUNG - Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 7th. Analysts expect Pulmonx to post earnings of ($0.37) per share and revenue of $22.03 million for the quarter.
Pulmonx (NASDAQ:LUNG - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.36) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.01. The company had revenue of $22.54 million during the quarter, compared to the consensus estimate of $22.03 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. On average, analysts expect Pulmonx to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Pulmonx Price Performance
NASDAQ:LUNG traded down $0.17 during trading hours on Monday, reaching $3.61. 253,327 shares of the company were exchanged, compared to its average volume of 312,712. The company has a market capitalization of $145.09 million, a P/E ratio of -2.53 and a beta of 0.65. The company has a debt-to-equity ratio of 0.40, a current ratio of 7.70 and a quick ratio of 6.77. The business has a 50 day moving average of $6.43 and a 200 day moving average of $6.53. Pulmonx has a 1-year low of $3.39 and a 1-year high of $10.01.
Insider Buying and Selling at Pulmonx
In related news, Director Glendon E. French III sold 20,000 shares of the firm's stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $7.85, for a total transaction of $157,000.00. Following the completion of the sale, the director now owns 991,974 shares of the company's stock, valued at $7,786,995.90. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Geoffrey Beran Rose sold 5,779 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.13, for a total transaction of $41,204.27. Following the transaction, the insider now owns 285,278 shares in the company, valued at $2,034,032.14. The trade was a 1.99 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 145,660 shares of company stock valued at $1,128,484. 6.80% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
LUNG has been the topic of a number of recent analyst reports. Piper Sandler restated an "overweight" rating and issued a $9.00 price target (down previously from $10.00) on shares of Pulmonx in a research report on Thursday. Morgan Stanley initiated coverage on shares of Pulmonx in a report on Monday, March 10th. They issued an "equal weight" rating on the stock. Citigroup assumed coverage on shares of Pulmonx in a research report on Monday, March 10th. They issued a "buy" rating for the company. Canaccord Genuity Group lowered their price objective on shares of Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a research report on Thursday. Finally, Jefferies Financial Group started coverage on Pulmonx in a research note on Monday, March 10th. They issued a "buy" rating on the stock. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Pulmonx has an average rating of "Moderate Buy" and an average price target of $12.07.
Read Our Latest Report on Pulmonx
About Pulmonx
(
Get Free Report)
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
See Also
Before you consider Pulmonx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.
While Pulmonx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
